ReviewThorax2007
Exacerbations in cystic fibrosis: 2 . prevention.
Review in Thorax, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 42 citations in OpenAlex.
- Robust identification of environmental exposures and community characteristics predictive of rapid lung disease progression.The Science of the total environment · 2024Article
- Evaluating precision medicine tools in cystic fibrosis for racial and ethnic fairness.Journal of clinical and translational science · 2024Article
- Quantification of Phenotypic Variability of Lung Disease in Children with Cystic Fibrosis.Genes · 2021Review
- The Detection of Bile Acids in the Lungs of Paediatric Cystic Fibrosis Patients Is Associated with Altered Inflammatory Patterns.Diagnostics (Basel, Switzerland) · 2020Article
- Pulmonary Function and Hospital Admission in Patients with Cystic Fibrosis Based on Household Second-Hand Smoking.Tanaffos · 2018Article
- Early detection of pulmonary exacerbations in children with Cystic Fibrosis by electronic home monitoring of symptoms and lung function.Scientific reports · 2017Observational
- Role of C-reactive protein as a biomarker for prediction of the severity of pulmonary exacerbations in patients with cystic fibrosis.BMC pulmonary medicine · 2014Article
- Treatment of pulmonary exacerbations in cystic fibrosis.European respiratory review : an official journal of the European Respiratory Society · 2013Review
- Toward implementation of quorum sensing autoinducers as biomarkers for infectious disease states.Analytical chemistry · 2013Article
- Inhaled hypertonic saline in adults hospitalised for exacerbation of cystic fibrosis lung disease: a retrospective study.BMJ open · 2012Article
- Life-space mobility is associated with frequency of hospitalization in adults with cystic fibrosis.The clinical respiratory journal · 2011Article
- Palivizumab, pneumococcal and influenza vaccination in cystic fibrosis.Journal of the Royal Society of Medicine · 2009Article
- Airway epithelial control of Pseudomonas aeruginosa infection in cystic fibrosis.Trends in molecular medicine · 2008Review
- Article
- Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatment.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e TisilogiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The life span of people with cystic fibrosis (CF) has increased dramatically over the past 50 years. Many factors have contributed to this improvement. Respiratory exacerbations of CF lung disease are associated with the need for hospitalisation and antibiotic treatment, reduction in the quality of life, fragmented sleep and mortality. A number of preventive treatment strategies have been developed to reduce the frequency and severity of respiratory exacerbations in CF including mucolytic agents, physiotherapy and exercise, antibiotics, nutritional strategies, anti-inflammatory treatments and vaccinations against common respiratory pathogens. The evidence for each of these treatments and their potential impact is discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.